Kuros Biosciences Dividend 2024

Dividend Details

Understanding Kuros Biosciences's Dividend Distributions

Kuros Biosciences’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Kuros Biosciences's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Kuros Biosciences's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Kuros Biosciences’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Kuros Biosciences Aktienanalyse

What does Kuros Biosciences do?

Kuros Biosciences AG is a leading Swiss biotech company specializing in the development of novel products for the regeneration of bones and soft tissues. Founded in 2004 in Zurich, the company has since experienced a remarkable history of scientific progress, partnerships, and growth. Kuros' business model is based on researching and developing innovative therapy products in the fields of orthopedics and traumatology. The company relies on proprietary technologies and products based on natural body processes and cellular signals. Kuros aims to reduce the use of autologous bone or tissue transplantation and improve patient care with this approach. The company is divided into three strategic business areas: orthobiologics, neurotherapeutics, and tissue repair. The orthobiologics area includes products for the regeneration and restoration of bone defects and injuries. Kuros has developed a novel synthetic bone matrix called MagnetOs, which supports bone growth due to its bioactive properties. The neurotherapeutics area focuses on therapy products for the treatment of neurological diseases such as strokes. Kuros utilizes its expertise in cellular signaling to develop targeted and effective therapies. The third business area, tissue repair, concentrates on the development of products for the repair of soft tissues and tendons. The company has created a variety of innovative solutions based on the body's own regeneration processes in this area. Research and development are at the center of Kuros' business model as a biotech company. The company aims to continually develop new products and therapy solutions to improve patient care in the fields of orthopedics, neurology, and tissue repair. Within this framework, Kuros closely collaborates with leading scientific institutions and partners from the pharmaceutical and medtech industries. Overall, Kuros Biosciences has developed an impressive range of products based on the latest scientific knowledge, offering comprehensive solutions for the regeneration of bones, soft tissues, and nerve cells. Kuros' core business lies in the targeted marketing and distribution of these products to medical professionals and clinics. Since its founding in 2004, Kuros Biosciences AG has experienced an exciting history of progress and growth. With an innovative business model, a strong focus on research and development, and a wide range of products, the company has established itself as a key player in the biotech industry. Kuros' success is based on close collaboration with leading scientists and partners, as well as a strong commitment to meeting the needs of patient care and medical professionals. Kuros Biosciences is one of the most popular companies on Eulerpool.com.

Frequently Asked Questions about Kuros Biosciences stock

How much dividend does Kuros Biosciences pay?

Over the past 12 months, Kuros Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kuros Biosciences is expected to pay a dividend of 0 CHF.

What is the dividend yield of Kuros Biosciences?

The current dividend yield of Kuros Biosciences is .

When does Kuros Biosciences pay dividends?

Kuros Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kuros Biosciences?

Kuros Biosciences paid dividends every year for the past 0 years.

What is the dividend of Kuros Biosciences?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kuros Biosciences located?

Kuros Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kuros Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kuros Biosciences from 11/17/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Kuros Biosciences pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Kuros Biosciences in the year 2023?

In the year 2023, Kuros Biosciences distributed 0 CHF as dividends.

In which currency does Kuros Biosciences pay out the dividend?

The dividends of Kuros Biosciences are distributed in CHF.